Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00117312
Status:
TERMINATED
Last Update Posted:
2011-05-23
First Post:
2005-06-30
Brief Title:
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
Sponsor:
Ferring Pharmaceuticals
Organization:
Ferring Pharmaceuticals
Study Overview
Official Title:
An Open-Label Multi-Center Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
Status:
TERMINATED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
After 190 weeks 7 patients left it was terminated for administrative reasons
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Participants responding well in Study FE200486 CS06 NCT00117949 were given the opportunity to continue treatment with degarelix under a clinical study until FE200486 was available on the market or until the study was discontinued
Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of FE200486
Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of FE200486
Detailed Description:
The data include participants from both the main study FE200486 CS06 NCT00117949 and the extension study FE200486 CS06A
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None